temozolomide has been researched along with Leukopenia in 11 studies
Leukopenia: A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To study the safety and efficacy of three-dimensional conformal radiotherapy in combination with temozolomide in treatment of patients with diffuse brainstem glioma." | 9.15 | [Safety and efficacy of three-dimensional conformal radiotherapy combined with temozolomide in treatment of diffuse brainstem gliomas]. ( Cai, CL; Fang, HH; Kang, JB; Li, FM; Nie, Q, 2011) |
| "The efficacy and safety of temozolomide were evaluated in 32 patients with anaplastic astrocytoma at first relapse." | 9.12 | [Efficacy and safety of monotherapy with temozolomide in patients with anaplastic astrocytoma at first relapse--a phase II clinical study]. ( Aoki, T; Fujimaki, T; Hori, T; Ikeda, J; Kochi, M; Maruno, M; Matsutani, M; Nakamura, H; Nishikawa, R; Sato, S; Sawamura, Y; Shibui, S; Sugiyama, K; Takahashi, H; Takahashi, J; Wakabayashi, T, 2006) |
| "Temozolomide (TMZ) has demonstrated activity and acceptable toxicity for the treatment of recurrent malignant gliomas in carious prospective phase II studies." | 9.12 | [Temozolomide in the treatment of recurrent malignant glioma]. ( Ishii, N; Iwasaki, Y; Kobayashi, H; Murata, J; Sawamura, Y, 2006) |
| "Temozolomide in the schedule used has as good activity in chemotherapy-naive metastatic melanoma as the other most active agents currently in use." | 9.08 | Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. ( Bleehen, NM; Brampton, M; Calvert, AH; Lee, SM; Newlands, ES; Rustin, GJ; Selby, P; Stevens, MF; Thatcher, N, 1995) |
| "Radiochemotherapy involving cisplatinum-based polychemotherapy is more toxic than radiotherapy in combination with temozolomide." | 5.48 | Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen : Acute toxicity in pediatric high-grade glioma patients. ( Bison, B; Bojko, S; Gielen, GH; Hoffmann, M; Kortmann, RD; Kramm, CM; Pietsch, T; Seidel, C; von Bueren, AO; Warmuth-Metz, M, 2018) |
| "Cabozantinib inhibits mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2) and has demonstrated activity in patients with recurrent glioblastoma, warranting evaluation of the addition of cabozantinib to radiotherapy (RT) and temozolomide (TMZ) for patients with newly diagnosed high-grade glioma." | 5.22 | Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. ( Chamberlain, MC; Cloughesy, T; Desjardins, A; Glantz, M; Mikkelsen, T; Reardon, DA; Schiff, D; Wen, PY, 2016) |
| "To study the safety and efficacy of three-dimensional conformal radiotherapy in combination with temozolomide in treatment of patients with diffuse brainstem glioma." | 5.15 | [Safety and efficacy of three-dimensional conformal radiotherapy combined with temozolomide in treatment of diffuse brainstem gliomas]. ( Cai, CL; Fang, HH; Kang, JB; Li, FM; Nie, Q, 2011) |
| "The efficacy and safety of temozolomide were evaluated in 32 patients with anaplastic astrocytoma at first relapse." | 5.12 | [Efficacy and safety of monotherapy with temozolomide in patients with anaplastic astrocytoma at first relapse--a phase II clinical study]. ( Aoki, T; Fujimaki, T; Hori, T; Ikeda, J; Kochi, M; Maruno, M; Matsutani, M; Nakamura, H; Nishikawa, R; Sato, S; Sawamura, Y; Shibui, S; Sugiyama, K; Takahashi, H; Takahashi, J; Wakabayashi, T, 2006) |
| "Temozolomide (TMZ) has demonstrated activity and acceptable toxicity for the treatment of recurrent malignant gliomas in carious prospective phase II studies." | 5.12 | [Temozolomide in the treatment of recurrent malignant glioma]. ( Ishii, N; Iwasaki, Y; Kobayashi, H; Murata, J; Sawamura, Y, 2006) |
| "Temozolomide in the schedule used has as good activity in chemotherapy-naive metastatic melanoma as the other most active agents currently in use." | 5.08 | Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. ( Bleehen, NM; Brampton, M; Calvert, AH; Lee, SM; Newlands, ES; Rustin, GJ; Selby, P; Stevens, MF; Thatcher, N, 1995) |
| "To evaluate the efficacy of temozolomide (TMZ) combined with cisplatin (CDDP) in terms of response rate, time to progression (TTP) and overall survival (OS), as well as the tolerability of the regimen in patients with brain metastases from solid tumors." | 2.71 | Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. ( Aravantinos, G; Bafaloukos, D; Bamias, A; Carina, M; Christodoulou, C; Klouvas, G; Linardou, H; Skarlos, D, 2005) |
| "Radiochemotherapy involving cisplatinum-based polychemotherapy is more toxic than radiotherapy in combination with temozolomide." | 1.48 | Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen : Acute toxicity in pediatric high-grade glioma patients. ( Bison, B; Bojko, S; Gielen, GH; Hoffmann, M; Kortmann, RD; Kramm, CM; Pietsch, T; Seidel, C; von Bueren, AO; Warmuth-Metz, M, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Seidel, C | 1 |
| von Bueren, AO | 1 |
| Bojko, S | 1 |
| Hoffmann, M | 1 |
| Pietsch, T | 1 |
| Gielen, GH | 1 |
| Warmuth-Metz, M | 1 |
| Bison, B | 1 |
| Kortmann, RD | 1 |
| Kramm, CM | 1 |
| Li, HL | 1 |
| Cui, XL | 1 |
| Zhang, JN | 1 |
| Lin, S | 1 |
| Schiff, D | 1 |
| Desjardins, A | 1 |
| Cloughesy, T | 1 |
| Mikkelsen, T | 1 |
| Glantz, M | 1 |
| Chamberlain, MC | 1 |
| Reardon, DA | 1 |
| Wen, PY | 1 |
| Jeong, JH | 1 |
| Hong, YS | 1 |
| Park, Y | 1 |
| Kim, J | 1 |
| Kim, JE | 1 |
| Kim, KP | 1 |
| Kim, SY | 1 |
| Park, JH | 1 |
| Kim, JH | 1 |
| Park, IJ | 1 |
| Lim, SB | 1 |
| Yu, CS | 1 |
| Kim, JC | 1 |
| Kim, TW | 1 |
| Fang, HH | 1 |
| Nie, Q | 1 |
| Kang, JB | 1 |
| Li, FM | 1 |
| Cai, CL | 1 |
| Christodoulou, C | 1 |
| Bafaloukos, D | 1 |
| Linardou, H | 1 |
| Aravantinos, G | 1 |
| Bamias, A | 1 |
| Carina, M | 1 |
| Klouvas, G | 1 |
| Skarlos, D | 1 |
| Koch, D | 1 |
| Wick, W | 1 |
| Yang, SH | 1 |
| Kim, MK | 1 |
| Lee, TK | 1 |
| Lee, KS | 1 |
| Jeun, SS | 1 |
| Park, CK | 1 |
| Kang, JK | 1 |
| Kim, MC | 1 |
| Hong, YK | 1 |
| Nishikawa, R | 1 |
| Shibui, S | 1 |
| Maruno, M | 1 |
| Sugiyama, K | 1 |
| Sato, S | 1 |
| Fujimaki, T | 1 |
| Takahashi, H | 1 |
| Wakabayashi, T | 1 |
| Takahashi, J | 1 |
| Kochi, M | 1 |
| Nakamura, H | 1 |
| Sawamura, Y | 2 |
| Ikeda, J | 1 |
| Hori, T | 1 |
| Aoki, T | 1 |
| Matsutani, M | 1 |
| Kobayashi, H | 1 |
| Ishii, N | 1 |
| Murata, J | 1 |
| Iwasaki, Y | 1 |
| Bleehen, NM | 1 |
| Newlands, ES | 1 |
| Lee, SM | 1 |
| Thatcher, N | 1 |
| Selby, P | 1 |
| Calvert, AH | 1 |
| Rustin, GJ | 1 |
| Brampton, M | 1 |
| Stevens, MF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Preoperative Chemoradiation With Capecitabine Plus Temozolomide in Patients With Locally Advanced Resectable Rectal Cancer: Phase I Study[NCT01781403] | Phase 1 | 22 participants (Actual) | Interventional | 2013-05-10 | Completed | ||
| Multicenter Phase II Study of Preoperative Chemoradiotherapy With CApecitabine Plus Temozolomide in Patients With MGMT Silenced and Microsatellite Stable Locally Advanced RecTal Cancer: the CATARTIC Trial[NCT05136326] | Phase 2 | 21 participants (Anticipated) | Interventional | 2021-12-01 | Recruiting | ||
| Phase II Study of Gamma Knife Radiosurgery and Temozolomide (Temodar) for Newly Diagnosed Brain Metastases[NCT00582075] | Phase 2 | 25 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The MTD is defined as the maximum dose level in the doses of temozolomide tested with capecitabine and radiation in which the incidence proportion of DLT exceeds 30%. (NCT01781403)
Timeframe: 5-6 weeks during study treatment
| Intervention | mg/m^2 (Number) |
|---|---|
| Dose Level 1 | 0 |
| Dose Level 2 | 0 |
| Dose Level 3/Recommended Dose | 0 |
"Pathologic responses and stages were classified according to Dworak's classification and the 7th edition of the American Joint Committee on Cancer staging system, respectively.~The pathologic complete response (pCR) was defined as the total regression of the primary tumor regardless of regional lymph nodal status (ypT0), with residual fibrotic mass or acellular mucin pools only, thus without detectable tumor cells." (NCT01781403)
Timeframe: at the time of surgery (6-8 weeks after study treatment)
| Intervention | participants (Number) |
|---|---|
| Unmethylated MGMT | 1 |
| Hypermethylated MGMT | 6 |
RD will be defined as one level below the MTD. (NCT01781403)
Timeframe: 5-6 weeks after CRT
| Intervention | mg/m^2 (Number) |
|---|---|
| Dose Level 1 | 0 |
| Dose Level 2 | 0 |
| Dose Level 3/Recommended Dose | 75 |
"Toxicity will be monitored and recorded every week during study treatment (5 or 6 weeks) as following according to the NCI-CTCAE version 4.0~An interval history and physical examination with particular attention to drug-induced side effects along with documentation of the patient's weight and performance status will be performed on each visit.~CBC with differential count, blood chemistry including calcium, phosphorus, glucose, BUN, creatinine, total protein, albumin, AST, ALT, alkaline phosphatase, total bilirubin, and electrolyte will be performed before next planned treatment.~All relevant information regarding drug dosage, laboratory examinations, and treatment-related toxicities must be recorded before each treatment is given.~Summaries of the frequency and severity of adverse effects are based on the worst episodes recorded." (NCT01781403)
Timeframe: 5-6 weeks during study treatment
| Intervention | events (Number) | |||
|---|---|---|---|---|
| Any grade 1 adverse event | Any grade 2 adverse event | Any grade 3 adverse event | Any grade 4 adverse event | |
| Dose Level 1 | 6 | 2 | 1 | 0 |
| Dose Level 2 | 8 | 2 | 0 | 0 |
| Dose Level 3/Recommended Dose | 60 | 17 | 3 | 0 |
(NCT00582075)
Timeframe: 2 years
| Intervention | weeks (Median) |
|---|---|
| Radiosurgery 15-24 Gy + Adjuvant Temozolomide | 31 |
Patients developing distant brain failure (DBF) at one year. An approximation method was used to arrive at the reported percentage. (NCT00582075)
Timeframe: 1 years
| Intervention | percentage of participants (Number) |
|---|---|
| Radiosurgery 15-24 Gy + Adjuvant Temozolomide | 37 |
9 trials available for temozolomide and Leukopenia
| Article | Year |
|---|---|
Chemotherapy alleviates subacute recurrent glioma-associated refractory cerebral edema by downregulating vascular endothelial growth factor.
Topics: Adult; Aged; Brain Edema; Brain Neoplasms; Cisplatin; Dacarbazine; Down-Regulation; Female; Glioma; | 2014 |
Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
Topics: Adult; Aged; Alanine Transaminase; Anilides; Antineoplastic Combined Chemotherapy Protocols; Asparta | 2016 |
Phase 1 Study of Preoperative Chemoradiation Therapy With Temozolomide and Capecitabine in Patients With Locally Advanced Rectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Dacarb | 2016 |
Phase 1 Study of Preoperative Chemoradiation Therapy With Temozolomide and Capecitabine in Patients With Locally Advanced Rectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Dacarb | 2016 |
Phase 1 Study of Preoperative Chemoradiation Therapy With Temozolomide and Capecitabine in Patients With Locally Advanced Rectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Dacarb | 2016 |
Phase 1 Study of Preoperative Chemoradiation Therapy With Temozolomide and Capecitabine in Patients With Locally Advanced Rectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Dacarb | 2016 |
[Safety and efficacy of three-dimensional conformal radiotherapy combined with temozolomide in treatment of diffuse brainstem gliomas].
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Injuries; Brain Stem Neoplasms; Chemorad | 2011 |
Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brea | 2005 |
Temozolomide chemotherapy in patients with recurrent malignant gliomas.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; | 2006 |
[Efficacy and safety of monotherapy with temozolomide in patients with anaplastic astrocytoma at first relapse--a phase II clinical study].
Topics: Adult; Aged; Anorexia; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; | 2006 |
[Temozolomide in the treatment of recurrent malignant glioma].
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; D | 2006 |
Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dacarbazine; Female; Humans; Leukopenia; Male; Melan | 1995 |
2 other studies available for temozolomide and Leukopenia
| Article | Year |
|---|---|
Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen : Acute toxicity in pediatric high-grade glioma patients.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chil | 2018 |
Higher dosing of temozolomide? Regression of an anaplastic oligoastrocytoma over more than three years.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Bone Marrow; Brain Neoplasms; Dacarbazine; Drug Over | 2006 |